Ive never had this much confidence before in my life! Alexis, 26 I never thought losing weightlet alone 130 pounds in 7 monthswas possible
Koska J, Sands M, Burciu C, et al
not yet FDA-approved 5.Gastrointestinal side effects (nausea, diarrhea, vomiting) are dose-dependent and similar to other GLP-1 agonists 6.Represents potential next-generation therapy beyond currently approved GLP-1 and GIP/GLP-1 agonists Quick Facts Overview Retatrutide (LY3437943) is a novel peptide therapeutic developed by Eli Lilly that represents the first-in-class triple receptor agonist
As a general guideline, Semaglutide GLP-1 injections are typically prescribed to individuals with a BMI of 30 or above or 27 and above with at least one weight-related condition, such as high cholesterol, osteoarthritis, or sleep apnea
Early research and growing examples suggest that addressing both hormonal decline with MHT and metabolic changes with GLP-1 therapy could result in greater weight loss and metabolic improvements compared to either approach alone
Zheng Z, et al
